First Trust Advisors LP Legend Biotech Corp Transaction History

First Trust Advisors LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	BUY	$55.06 - $69.99 $1.15 Million - $1.46 Million	20,845 Added 87.55%	44,653 $2.5 Million
Q4 2023 Feb 13, 2024	SELL	$57.25 - $69.74 $1.74 Million - $2.12 Million	-30,351 Reduced 56.04%	23,808 $1.43 Million
Q3 2023 Nov 13, 2023	BUY	$63.16 - $76.5 $345,485 - $418,455	5,470 Added 11.23%	54,159 $3.64 Million
Q2 2023 Aug 14, 2023	SELL	$46.28 - $75.01 $2.44 Million - $3.96 Million	-52,771 Reduced 52.01%	48,689 $3.36 Million
Q1 2023 May 15, 2023	SELL	$43.42 - $57.37 $9.78 Million - $12.9 Million	-225,191 Reduced 68.94%	101,460 $4.89 Million
Q4 2022 Feb 09, 2023	BUY	$38.8 - $55.46 $2.96 Million - $4.23 Million	76,315 Added 30.49%	326,651 $16.3 Million
Q3 2022 Nov 14, 2022	BUY	$38.15 - $57.1 $6.6 Million - $9.88 Million	172,980 Added 223.62%	250,336 $10.2 Million
Q2 2022 Aug 12, 2022	SELL	$33.54 - $55.0 $49,840 - $81,730	-1,486 Reduced 1.88%	77,356 $4.26 Million
Q1 2022 May 13, 2022	SELL	$31.02 - $48.18 $817,408 - $1.27 Million	-26,351 Reduced 25.05%	78,842 $2.87 Million
Q4 2021 Feb 08, 2022	BUY	$41.14 - $56.98 $4.33 Million - $5.99 Million	105,193 New	105,193 $4.9 Million

198

74.2M

374K

387K

Ticker LEGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 167,403,008
Market Cap $8.5B
Description
Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multipl...

Get notified when there are updates to the investment portfolio of First Trust Advisors LP, based on Form 13F filings with the SEC.

Stay updated on First Trust Advisors LP with notifications on news.